Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Fu Wai Hospital, Beijing, China
- Target Recruit Count
- 252
- Registration Number
- NCT06090890
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital, Beijing, Beijing, China
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT06078969
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT06047080
- Locations
- 🇩🇪
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany
🇺🇸Kaiser Permanente Medical Ctr, Vallejo, California, United States
🇺🇸St. Luke's Hospital, Chesterfield, Missouri, United States
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06043323
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06045247
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Tom Appleton
- Target Recruit Count
- 30
- Registration Number
- NCT06037811
- Locations
- 🇨🇦
St. Joseph's Health Care, London, Ontario, Canada
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 180
- Registration Number
- NCT05959720
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Fate Therapeutics
- Registration Number
- NCT05934097
The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 120
- Registration Number
- NCT05931744
- Locations
- 🇪🇬
Kafrelsheikh University hospital, Kafrelsheikh, Egypt
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05922761
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.